Tri Locum Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Tri Locum Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-89,525	Closed	-$29.2M	–	19
2025 Q2	$29.2M	Buy	+89,525	New	+$24.8M	8.86%	3
2024 Q3	–	Sell	-45,000	Closed	-$10.9M	–	21
2024 Q2	$10.9M	Buy	+45,000	New	+$7.1M	2.76%	16
2023 Q3	–	Sell	-29,506	Closed	-$5.6M	–	63
2023 Q2	$5.6M	Buy	+29,506	New	+$5.85M	2.08%	22

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Tri Locum Partners's ALNY Position: Q3 2025 in Review

Tri Locum Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 89,525 shares — an estimated $29.2M sold.

Tri Locum Partners first reported a position in ALNY in Q2 2023 and held it in 3 quarters. The position peaked at $29.2M in Q2 2025. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

Tri Locum Partners reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Tri Locum Partners sold 89,525 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $29.2M.
Tri Locum Partners first reported a position in Alnylam Pharmaceuticals in Q2 2023 and held it in 3 quarters.
Tri Locum Partners's Alnylam Pharmaceuticals position peaked at $29.2M in Q2 2025.
821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Tri Locum Partners's 13F filing for Q3 2025, filed 14 Nov 2025.